Clopidogrel, a novel antiplatelet agent, and digoxin: Absence of pharmacodynamic and pharmacokinetic interaction

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue SUPPL. 2, 1999, Pages 51-54

  Peeters, Pierre A M ^a,b   Crijns, H J M J ^b   Tamminga, Wim J ^b   Jonkman, Jan H G ^b   Dickinson, John P ^c   Necciari, José ^d  

^a NV ORGANON   (Netherlands)

^b PRA International USA   (Netherlands)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d SANOFI   (France)

Author keywords

Clopidogrel interaction; Digoxin pharmacokinetics; Digoxin clopidogrel safety

Indexed keywords

CLOPIDOGREL; DIGOXIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; DIGOXIN BLOOD LEVEL; DROWSINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG EXCRETION; DRUG SAFETY; HEADACHE; HEART DISEASE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; DIGOXIN; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 0032801260     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. st ed. London: Pharmaceutical Press; 1996;852-856
2. Vargas R, Reitman M, Teitelbaum P, et al. Study of the effect of ticlopidine on digoxin blood levels. Clin Pharmacol Ther 1988;43:176
3. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
4. Born GVR, Cross J. The aggregation of blood platelets. J Physiol 1963;168:178-195
5. Hoffman BF, Bigger JT. Digitalis and allied cardiac glycosides. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's Pharmacological Basis of Therapeutics. 8th Edition. New York: Macmillan Publishing; 1990; 814-839
6. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450 IA. Thromb Haemost 1994;72:313-317
7. Guillin MC, Bonnet G, Sissmann J, Necciari J, Dickinson JP. Pharmacodynamics and pharmacokinetics of the novel antiplatelet agent, clopidogrel, in the young and the elderly with and without symptomatic atherosclerosis. Abstract P916, Eur Heart J 1996; 17:161(Abst)
8. Denninger MH, Necciari J, Serre-Lacroix E, Sissmann J. Clopidogrel antiplatelet activity is independent of age, presence of atherosclerosis. Semin Thromb Hemostas 1999;25(Suppl 2): 41-46
9. CD Forbes, Lowe GDO, MacLaren M, et al. Clopidogrel compatibility with concomitant cardiac co-medication: A study of its interactions with a beta-blocker and a calcium uptake antagonist. Semin Thromb Hemostas 1999;25(Suppl 2):55-60
10. Boneu B, Destelle G, on behalf of the Study Group. Platelet antiaggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemostas 1996;76:939-943